Rising evidentiary standards, pricing pressure and policy changes are redefining what it takes for pharmaceutical products to succeed.

Pharmaceutical companies must rethink how R&D decisions are made, ensuring that clinical trial designs reflect the kind of evidence required for access and optimal reimbursement. Unfortunately, in too many companies, clinical development processes are out of step with evolving evidence requirements.